• 1. Aggregation-induced emission based on a fluorinated macrocycle: visualizing spontaneous and ultrafast solid-state molecular motions at room temperature via F?F interactions?
  Mei Zhang,Jingjing Guo,Tingting Liu,Zhanyu He,Majeed Irfan,Zujin Zhao,Zhuo Zeng J. Mater. Chem. C, 2020,8, 14919-14924
• 2. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 3. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 4. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 5. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azaspirodecane derivatives Azaspirodecane derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azaspirodecane derivatives

Introduction to 1-Azaspiro[4.5]decan-2-one (CAS No. 5498-74-8)

1-Azaspiro[4.5]decan-2-one, identified by its Chemical Abstracts Service (CAS) number 5498-74-8, is a heterocyclic compound that has garnered significant attention in the field of medicinal chemistry and drug discovery. This bicyclic structure, featuring a nitrogen-containing spirocyclic core, presents a unique framework that has been explored for its potential pharmacological properties. The compound’s molecular architecture, characterized by a spiro linkage between a five-membered and a six-membered ring, offers a versatile scaffold for chemical modifications and functionalization, making it an attractive candidate for further investigation.

The spirocyclic nature of 1-Azaspiro[4.5]decan-2-one contributes to its distinct conformational flexibility and reactivity, which are critical factors in medicinal chemistry. This structural motif has been increasingly recognized for its ability to interact with biological targets in novel ways, potentially leading to the development of new therapeutic agents. The presence of a ketone group at the 2-position further enhances its chemical diversity, allowing for various derivatization strategies that can modulate its biological activity.

Recent advancements in the field of heterocyclic chemistry have highlighted the importance of spirocyclic compounds in drug design. Spirocycles are known for their ability to exhibit high binding affinity and selectivity due to their rigid yet adaptable structures. In particular, 1-Azaspiro[4.5]decan-2-one has been studied for its potential role in inhibiting enzymes and receptors involved in various diseases, including neurological disorders and inflammatory conditions.

One of the most compelling aspects of 1-Azaspiro[4.5]decan-2-one is its structural similarity to natural products that have demonstrated significant biological activity. For instance, related spirocyclic compounds have been found to possess antimicrobial and anti-inflammatory properties, suggesting that 1-Azaspiro[4.5]decan-2-one may also exhibit such effects. This hypothesis has been supported by computational studies that predict favorable interactions between the compound and biological targets such as kinases and proteases.

The synthesis of 1-Azaspiro[4.5]decan-2-one presents both challenges and opportunities for chemists. Traditional synthetic routes often involve multi-step processes that require careful optimization to achieve high yields and purity. However, recent methodologies have leveraged transition metal catalysis and asymmetric synthesis to streamline these processes, making the preparation of complex spirocyclic compounds more accessible than ever before.

From a pharmacological perspective, the nitrogen atom in the spirocyclic ring of 1-Azaspiro[4.5]decan-2-one offers a site for further functionalization, enabling the creation of derivatives with enhanced potency and selectivity. Researchers have explored various strategies, including N-substitution with different alkyl or aryl groups, which can modulate the compound’s pharmacokinetic properties. Additionally, modifications at other positions on the molecule have revealed novel bioactivities that may be relevant for treating conditions such as pain, cancer, and neurodegenerative diseases.

The growing interest in 1-Azaspiro[4.5]decan-2-one has led to several preclinical studies aimed at evaluating its biological activity. Initial findings suggest that this compound exhibits promising effects on certain disease models, although further research is needed to fully elucidate its mechanism of action and potential side effects. These studies often involve in vitro assays to assess enzyme inhibition and cell-based models to evaluate cytotoxicity and efficacy.

In conclusion, 1-Azaspiro[4.5]decan-2-one (CAS No. 5498-74-8) represents a structurally intriguing compound with significant potential in medicinal chemistry. Its unique spirocyclic framework, combined with its chemical versatility, makes it an attractive scaffold for developing new therapeutic agents. As research continues to uncover new applications for this molecule, it is likely that 1-Azaspiro[4.5]decan-2-one will play an increasingly important role in the discovery and development of innovative treatments for various human diseases.

• 5845-62-5(1-cyclohexyl-5-{[2-(4-ethoxyphenoxy)ethyl]sulfanyl}-1H-tetrazole)
• 6139-32-8(2-Pyrrolidinone,5-cyclohexyl-5-ethyl-)
• 607733-73-3(1-AZASPIRO[4.5]DECAN-2-ONE, 7,7,9,9-TETRAMETHYL-)
• 138816-39-4(2H-Indol-2-one, octahydro-7a-methyl-5-(1-methylethyl)-)
• 1251008-10-2(8-Amino-1-Azaspiro4.5Decan-2-One)
• 14293-08-4(2-Pyrrolidinone, 5-(cyclohexylmethyl)-)
• 19464-67-6(4-methyl-1-Azaspiro[4.5]decan-2-one)
• 6139-33-9(5-cyclohexyl-5-propylpyrrolidin-2-one)
• 6139-31-7(5-cyclohexyl-5-methylpyrrolidin-2-one)
• 3725-89-1(N-(tricyclo[3.3.1.1~3,7~]dec-1-yl)pentanamide)